Viking Therapeutics Director Rouan bought 1,240 shares at $24.15 on 2025-03-31 ($29,942.78); stock now -68.7% from 52-week high of $82.00
Rouan Sarah Kathryn, a Director of Viking Therapeutics, purchased 1,240 shares at $24.15 on 2025-03-31, establishing an initial position of 1,240 shares valued at $29,942.78. The transaction occurred at a significant discount to the stock's 52-week high of $82.00, with the stock currently trading -68.7% below that peak and down -37.6% over the past 90 days. The company is unprofitable with net income of $-24,940,000.00 for the most recent full fiscal year and $0.00 in latest quarter revenue. The purchase represents a board member's capital deployment in a clinical-stage biotech company amid a substantial drawdown from its recent highs, though the limited transaction size and new holder status provide limited evidence of conviction magnitude.